## Principles of Systemic Therapy (BRAIN-D)

### Page 1 of 6

**Anaplastic gliomas**

*Internal request:*
Review the data for cyclophosphamide as a recurrence/salvage therapy treatment option for anaplastic gliomas.

**Panel Discussion:**
Based on discussion, the panel consensus was to change cyclophosphamide from a category 2A to a category 2B recommendation as a recurrence/salvage therapy treatment option for anaplastic gliomas.

**References**


### Glioblastoma

*Internal request:*
Review the data for cyclophosphamide as a recurrence/salvage therapy treatment option for glioblastoma.

**Panel Discussion:**
Based on discussion, the panel consensus was to change cyclophosphamide from a category 2A to a category 2B recommendation as a recurrence/salvage therapy treatment option for glioblastoma.

**References**


### Internal request:
Institutional review comment to add procarbazine/lomustine/vincristine (PCV) with RT (category 1) for the treatment of 1p19q co-deleted anaplastic oligodendrogliomas

**Panel Discussion:**
Based on panel discussion and data in the noted reference, the panel consensus was to add RT and PCV for 1p19q co-deleted (category 1) for the adjuvant treatment of Anaplastic Oligoastrocytoma Anaplastic Oligodendroglioma. This is a new section.

**References**


### Page 2 of 6

**Primary CNS Lymphoma**

*Internal Request:*
Suggestion was made to add “Cisplatin, high-dose cytarabine, and dexamethasone” to the list of treatment options for Primary CNS Lymphoma that is recurrent or progressive.

**Panel Discussion:**
Based on discussion the panel consensus was to add “Cisplatin, high-dose cytarabine, and dexamethasone” to the list of treatment options for Primary CNS Lymphoma that is recurrent or progressive.

**References**


**Meningioma**

*Internal Request:*
Review the data for the list of systemic therapy options for the treatment of meningioma.

**Panel Discussion:**
Based on discussion, the panel consensus was to change hydroxyurea and interferon alfa from category 2A recommendations to category 2B recommendations for the treatment of meningioma.

**References**

- Hydroxyurea
- Interferon alfa

<table>
<thead>
<tr>
<th>References</th>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxyurea</td>
<td>17</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Interferon alfa</td>
<td>17</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>
### Guideline Page and Request

**Principles of Systemic Therapy (BRAIN-D)**

**Panel Discussion**

Based on discussion, the panel consensus was to change interferon alfa from a category 2A to a category 2B recommendation for the treatment of leptomeningeal metastases.

**References**

**Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

**Internal Request:**

Review the data for the list of Intra-CSF chemotherapy options for the treatment of leptomeningeal metastases.